TABLE 4.
Baseline recipient, donor, and perioperative characteristics of prospective amiodarone discontinuation cohort
| Baseline recipient characteristics | Prospective amiodarone discontinuation cohort (n = 28) |
|---|---|
| Age (y) | 55.9 ± 10.3 |
| Female sex (%) | 3 (10.7) |
| NICM (%) | 22 (78.6) |
| Diabetes (%) | 11 (39.3) |
| Hypertension (%) | 20 (71.4) |
| CKD (%) | 13 (46.4) |
| BMI (kg/m2) | 29.9 ± 7.3 |
| ICD/CRT-D (%) | 25 (89.3) |
| Duration of CF-LVAD support (m) | 27.7 ± 15.7 |
| Aspirin (%) | 19 (67.9) |
| ACE-I/ARB (%) | 10 (35.7) |
| Beta-blocker (%) | 24 (85.7) |
| Aldosterone antagonist (%) | 7 (25.0) |
| Sildenafil (%) | 8 (28.6) |
| Coumadin (%) | 27 (96.4) |
| Amiodarone total dose (mg/d) | 250.0 ± 79.3 |
| Indication for amiodarone | |
| Atrial fibrillation (%) | 10 (35.7) |
| Ventricular tachyarrhythmia (%) | 17 (60.7) |
| Frequent premature ventricular ectopy (%) | 1 (3.6) |
| Duration of amiodarone use (d) | 534.5 ± 673.3 |
| Baseline donor data characteristics | Prospective amiodarone discontinuation cohort (n = 9) |
| Age (y) | 36.3 ± 10.4 |
| Female sex (%) | 3 (33.3) |
| BMI (kg/m2) | 29.2 ± 7.5 |
| Anoxia as cause of death (%) | 6 (66.7) |
| CPR time (min) | 28.3 ± 32.4 |
| LVEF (%) | 57.2 ± 2.6 |
| Perioperative data characteristics | Prospective amiodarone discontinuation cohort (n = 9) |
| Dual organ transplant (%) | 1 (11.1) |
| Total ischemic time (min) | 205.1 ± 40.6 |
| Total CPB time (min) | 194.3 ± 76.2 |
| Intraoperative RBC transfusion (mL) | 500.0 ± 580.9 |
| Intraoperative FFP transfusion (mL) | 506.2 ± 581.6 |
| Intraoperative platelet transfusion (mL) | 343.4 ± 291.2 |
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CF-LVAD, continuous-flow left ventricular assist device; CKD, chronic kidney disease; CPB, cardiopulmonary bypass; CPR, cardiopulmonary resuscitation; CRT-D, cardiac resynchronization therapy defibrillator; FFP, fresh frozen plasma; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NICM, nonischemic cardiomyopathy; RBC, red blood cell.